Peroxisome Proliferator Activated Receptor Ligands as Regulators of Airway Inflammation and Remodelling in Chronic Lung Disease
2007
PPAR Ligands and Airway Inflammation in Chronic Lung Disease
publication
Evidence: moderate
Author Information
Author(s): Jane Elizabeth Ward, Tan Xiahui
Primary Institution: University of Melbourne
Hypothesis
PPARs may serve as additional therapeutic targets to control inflammation in chronic lung diseases like asthma.
Conclusion
PPAR ligands have shown potential in reducing airway inflammation and remodelling in chronic lung diseases.
Supporting Evidence
- PPARs are involved in regulating inflammation in the lungs.
- PPAR ligands can reduce the production of proinflammatory cytokines.
- In murine models, PPAR ligands decreased airway hyperresponsiveness.
Takeaway
This study suggests that certain drugs can help reduce inflammation in the lungs, which is important for people with asthma.
Methodology
The review summarizes in vitro and in vivo evidence regarding the effects of PPAR ligands on airway inflammation.
Limitations
The review is based on existing studies and does not present new experimental data.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website